Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

N.C. Bill Gives Students 'Vital Access' To Accurate Sex Education Instruction, Editorial States
A bill (S. 221) approved by the North Carolina Legislature that would require a public school sex education curriculum covering abstinence, contraception and sexually transmitted infections "will be the most comprehensive and science-based approach the state has used" for sex education, a Charlotte Observer editorial states, adding that Gov. Bev Perdue (D) "should sign it." The bill would require all public school districts in the state to teach a curriculum that focuses on abstinence but also includes information on preventing pregnancy and STIs. Parents would be able to have their children removed from the comprehensive portions of instruction. According to the editorial, the measure "still gives parents a choice in deciding what kind of sex education their children will receive." The editorial adds, "It also finally provides a curriculum that gives N.C. students vital access to age-appropriate, science-based information critical to their health, safety and well-being," which is "the kind of information that can help them make smart choices in serious situations."Parents are "often the best people for kids to turn to for advice and information" on sex, but "not all children have parents who can provide it, or are even willing to," and "not all children [who] go to their parents adhere to their advice," the editorial states. It continues, "The schools provide another avenue to get this critical advice and information -- and state lawmakers are right to make it available." According to the Observer, North Carolina has the ninth-highest teenage pregnancy rate in the U.S., and about "20,000 teenagers will get pregnant in North Carolina this year." A "comprehensive, science-based education program can help reduce the number of unintended teen pregnancies" and help reduce the spread of STIs, the editorial says. It concludes, "By reaching agreement on this matter, state lawmakers have given the children of this state vital tools to safeguard their health and welfare. ... Perdue should sign this bill and make it law" (Charlotte Observer, 6/26).
generic viagra online
Anti-Inflammatory Drugs May Defeat A Treatment-Resistant Type Of Cancer
Effective drugs for treating a chemotherapy-resistant form of lymphoma might already be on the market according to a study that has pieced together a chemical pathway involved in the disease.
News of the day
Hip And Back Fractures Increase Mortality Rates In People Older Than 50
Vertebral and hip fractures are associated with an increased risk of death, found a new study of 7753 people in Canada aged 50 years and older published in CMAJ (Canadian Medical Association Journal). According to the results, approximately 25% of people (both men and women) living in the community who develop a hip fracture and 16% who develop a spine fracture will die over a 5 year period.
Public Health

Poxel SAS Set Up To Find Innovative Solutions For Metabolic Diseases Management

Poxel is a research integrated pharmaceutical Company (RIPCO), spun out from Merck Serono a division of Merck KGaA, Germany, following the decision of Merck Serono to no longer invest in diabetes research and development. It aims to advance promising assets for cardio-metabolic diseases (with a primary focus on Type 2 diabetes) from Research to Phase 2 Clinical Proof-of-Concept, before out-licensing these projects to major pharmaceutical companies. Its pipeline consists only of innovative projects with new mechanisms of action, with a combined activity on glucose metabolism and other cardiovascular risk factors (lipid disorders and obesity) and with an improved safety profile compared to currently available therapies. Poxel has secured several programs from the Merck Serono pipeline. These include a first-in-class project, Imeglimin -which has already achieved its clinical proof-of-concept for the Type 2 diabetes monotherapy indication- and other projects from the Research until close to clinical development stages. Poxel"s management is composed of a tight and seasoned team of professionals who previously led the Merck Serono diabetes franchise from Research to Clinical & Commercialization. They have a proven track record in the pharmaceutical industry and extensive skills both in project management and technical expertise. The whole management team has an integrated strategic and operational view of the product value chain, from Research to Marketing, covering the complete product life cycle. Poxel"s team will perform and coordinate all work required in the following areas: research, preclinical, clinical and business development, with a strong focus on cardio-metabolic diseases. A focused and streamlined development of the company assets will ensure a successful out-licensing of those assets. All this provides Poxel with a significant competitive advantage. Poxel"s team will be advised by a highly regarded scientific Advisory Board in Endocrinology and Nutrition from the US and Europe. Poxel will start the development of its core assets, while seeking funding in order to create additional value from its unique pipeline. Neither Merck KGaA nor Merck Serono is shareholders of Poxel. About Type 2 Diabetes Type 2 Diabetes is defined by a failure of sensitive tissues to respond to insulin, a hormone involved in glucose and fatty acid metabolism, Type 2 diabetes hence being known as non-insulin-dependent diabetes. 90% of diabetic patients in the world suffer from type 2 diabetes. In 2007, more than 220 million people suffered from Type 2 diabetes worldwide, including over 65 million patients in the US and Europe. It is predicted that more than 300 million patients will have this disease by 2025 (IDF). The market is about EUR bn9.6 turnover in 2007, expected to reach EUR bn15 by 2016. Existing therapies on the market are dominated by few dominant product classes, but significant unmet needs remain. Poxel SAS


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009